Neoantigen × AI
Daily research signal
№50Brief

Neoantigen vaccines reliably activate T-cells; survival benefit lags

Personalized neoantigen vaccines are posting clinical signals in tumors where immunotherapy has historically failed, with today's items spanning glioblastoma, pancreatic cancer, and melanoma.DocWireNewsPubMedWTVG

The tension to watch: durable T-cell activation is now reproducible across platforms, but translation into survival benefit remains the exception—a 120-trial PDAC review makes that gap explicit.PubMed With Moderna/Merck framed as the field's first mover, competitive differentiation is shifting from proof-of-concept to strategy.PubMed

1new story3 in context
Commerciallast weekNew

Moderna/Merck-first out of the gate with a personal neoantigen cancer vaccine-who else is in the race and what strategy(ies) will win?

A commercial analysis positions Moderna/Merck as first out of the gate with a personalized neoantigen cancer vaccine and asks who else is in the race—and which strategies will win. Only the title was available, but the framing is the investor takeaway: with a first mover established, competitive differentiation now hinges on which strategies win rather than on proof-of-concept itself.

europepmc · last week · Fritsch EF, Wu CJ.

03

Relevant work from earlier we're still surfacing — not today's news.